Cannabigerol Antidepressant Formulation Reducing Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant medications for mood disorders, such as heterocyclic antidepressants, monoamine oxidase inhibitors, and lithium, often come with significant side effects and are unsuitable for certain patients, while cannabinoids like THC can exacerbate mood disorders.
Innovation Solution
Cannabigerol (CBG), a naturally occurring cannabinoid precursor to CBD, THC, and CBC, is used in high concentrations in pharmaceutical formulations for treating depression, either alone or in combination with other cannabinoids like CBD and CBC, to provide antidepressant effects with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antidepressants (HCAs, MAOIs, lithium) are used to treat depression, then antidepressant effect is achieved, but significant side effects occur
Solution Approach 1:
The patent extracts and isolates the beneficial antidepressant property from the harmful side effects by using CBG as a single isolated cannabinoid compound, rather than using traditional antidepressants that inherently produce significant side effects. This extraction principle separates the therapeutic effect from the adverse reactions.
Solution Approach 2:
CBG acts as an intermediary substance that provides antidepressant effects through a different mechanism than traditional antidepressants. It interacts with the endocannabinoid system rather than directly affecting monoamine reuptake or oxidative deamination, thereby achieving therapeutic effects without the typical side effects of HCAs, MAOIs, or lithium.
2Ease of operation
If cannabinoids like THC are used, then mood effects are produced, but mood disorders are exacerbated
Solution Approach 1:
The patent segments the cannabinoid class into specific individual compounds with distinct effects. By isolating CBG from other cannabinoids like THC, it identifies a specific segment (CBG) that provides therapeutic benefits without the harmful effects associated with other segments (THC) of the same class.
Solution Approach 2:
Different cannabinoids within the cannabis plant have different local qualities or specific properties. CBG possesses unique local quality characteristics that differ from THC, specifically providing antidepressant effects without the mood disorder exacerbation associated with THC. The patent exploits this local quality difference to achieve therapeutic effects without adverse reactions.
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.